Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

Figure 3

Radiotherapy combined with anti-PD-L1 and anlotinib could significantly potentiate the tumor immune microenvironment compared with other treatment combinations. Quantitative data and flow cytometric analysis of CD45⁺ T cells (a), CD4⁺T cells (b), CD8⁺ T cells (c), MDSCs (d), and M1 cells and M2 cells (e) in tumors. CTRL: control; RT: radiotherapy; IO: immunotherapy; AN: anlotinib.

(a)

(b)

(c)

(d)

(e)